Specifically, the product of KIF5B-RET activated multiple RTKs, including EGFR, providing vulnerabilities that could be targeted using combinations such as sorafenib with erlotinib or paclitaxel as potential treatment options for KIF5B-RET-positive non-small cell lung cancer (NSCLC). This evidence concerns the gene RET and non-small cell lung carcinoma.